These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3531415)

  • 1. Hypertension and other complications in human obesity.
    Björntorp P
    J Clin Hypertens; 1986 Jun; 2(2):163-5. PubMed ID: 3531415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes.
    Bonen A; Tandon NN; Glatz JF; Luiken JJ; Heigenhauser GJ
    Int J Obes (Lond); 2006 Jun; 30(6):877-83. PubMed ID: 16418758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diazoxide prevents abdominal adiposity and fatty liver in obese OLETF rats at prediabetic stage.
    Guo Z; Bu S; Yu Y; Ghatnekar G; Wang M; Chen L; Bu M; Yang L; Zhu B; Feng Z; Huang Q
    J Diabetes Complications; 2008; 22(1):46-55. PubMed ID: 18191077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance?
    Sarafidis PA; Bakris GL
    J Hum Hypertens; 2007 Jan; 21(1):12-9. PubMed ID: 17051236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperinsulinemia, insulin resistance, and hypertension.
    Bönner G
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S39-49. PubMed ID: 7898093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of insulin, glucagon, lactate, and nonesterified fatty acids to glucose in visceral obesity with and without NIDDM: relationship to hypertension.
    Iannello S; Campione R; Belfiore F
    Mol Genet Metab; 1998 Mar; 63(3):214-23. PubMed ID: 9608544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biological characteristics of arterial systolic hypertension in relation to the degree of obesity in a middle aged active population].
    Filipovsky J; Ducimetière P
    Arch Mal Coeur Vaiss; 1993 Aug; 86(8):1173-5. PubMed ID: 8129523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance, hyperinsulinemia and hypertension.
    Weidmann P; de Courten M; Böhlen L
    J Hypertens Suppl; 1993 Dec; 11(5):S27-38. PubMed ID: 8158379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Obesity in type 2 diabetes, its features and specificity].
    Xiang KS; Jia WP; Lu JX; Tang JL; Li J
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(21):1768-72. PubMed ID: 15631769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of abdominal obesity in pathogenesis of insulin resistance syndrome].
    Almazov VA; Blagosklonnaia IaV; Shliakhto EV; Krasil'nikova EI
    Ter Arkh; 1999; 71(10):18-22. PubMed ID: 10612167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The road from obesity to type 2 diabetes.
    Ioannidis I
    Angiology; 2008; 59(2 Suppl):39S-43S. PubMed ID: 18505743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms of insulin resistance and associated diseases.
    Mlinar B; Marc J; Janez A; Pfeifer M
    Clin Chim Acta; 2007 Jan; 375(1-2):20-35. PubMed ID: 16956601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of abdominal obesity and high susceptibility of cardiometabolic risk to its increments among Turkish women: a prospective population-based study.
    Onat A; Sari I; Hergenç G; Yazici M; Uyarel H; Can G; Sansoy V
    Metabolism; 2007 Mar; 56(3):348-56. PubMed ID: 17292723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The origins and consequences of obesity. Diabetes.
    Björntorp P
    Ciba Found Symp; 1996; 201():68-80; discussion 80-9, 188-93. PubMed ID: 9017275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nocturnal free fatty acids are uniquely elevated in the longitudinal development of diet-induced insulin resistance and hyperinsulinemia.
    Kim SP; Catalano KJ; Hsu IR; Chiu JD; Richey JM; Bergman RN
    Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1590-8. PubMed ID: 17264230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hypertension and obesity].
    Raison J; Pannier B; Blacher J; Safar M
    Arch Mal Coeur Vaiss; 2000 Nov; 93(11 Suppl):1423-8. PubMed ID: 11190291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage.
    Raz I; Eldor R; Cernea S; Shafrir E
    Diabetes Metab Res Rev; 2005; 21(1):3-14. PubMed ID: 15386813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levels of C3 in patients with severe, morbid and extreme obesity: its relationship to insulin resistance and different cardiovascular risk factors.
    Hernández-Mijares A; Jarabo-Bueno MM; López-Ruiz A; Solá-Izquierdo E; Morillas-Ariño C; Martínez-Triguero ML
    Int J Obes (Lond); 2007 Jun; 31(6):927-32. PubMed ID: 17264851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppressed gene expression of adipocyte resistin in an insulin-resistant rat model probably by elevated free fatty acids.
    Juan CC; Au LC; Fang VS; Kang SF; Ko YH; Kuo SF; Hsu YP; Kwok CF; Ho LT
    Biochem Biophys Res Commun; 2001 Dec; 289(5):1328-33. PubMed ID: 11741341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Obesity: entrance port to multimorbidity].
    Sailer D
    Wien Med Wochenschr; 1998; 148(17):388-92. PubMed ID: 9887499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.